Drug Development

The Rainwater Foundation awards $600,000 to pioneering scientists, accelerating breakthroughs in treating devastating neurodegenerative tauopathies.

TransCode Therapeutics and Quantum Leap are targeting hidden cancer cells with a novel RNA drug in a pivotal trial that could prevent colorectal cancer relapse.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

iVeena promotes key execs as it prepares for clinical trials of a novel eye drop that could reshape pediatric myopia treatment worldwide.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.